Guilin Sanjin Pharmaceutical announced that its wholly-owned subsidiary, Sanjin Group Hunan Sanjin Pharmaceutical, has had its lamotrigine tablets expected to be selected in the 12th national centralized drug procurement. The product specification is 25 mg, 48 tablets per box, with a procurement cycle from the date the selection results are implemented until December 31, 2029. Lamotrigine tablets are used to treat epilepsy. In 2025, sales revenue was 73.8999 million yuan, accounting for 3.61% of the company's 2025 operating revenue. The company stated that this expected selection will help promote product sales and market expansion, and enhance brand influence, but there is still uncertainty regarding the signing of procurement contracts and subsequent market sales execution.
Guilin Sanjin Pharmaceutical Co LtdLamotrigine tablets expected to be selected in national procurement, boosting sales and market expansion.